


CLAIMS

1. A compound of Formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is phenyl optionally substituted with one or more halo substituents;

R² is H or fluoro;

X¹ is CH₂ or O;

R⁴ is a mono or bicyclic heteroaryl, optionally substituted with one or more R³ substituents;

each R³ is independently selected from C₆₋₁₀aryl, benzyl, C₁₋₆alkyl, C₃₋₇cycloalkoxy, hydroxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, halo, haloC₁₋₆alkyl, OR⁵, CN, C(O)OC₁₋₆alkyl, OH, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH₂, and NR^aR^b, wherein R^a and R^b are independently H, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl or halo C₁₋₆alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C₃₋₇cycloalkyl, C₃₋₇cycloalkoxy, NH₂, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, -S-C₁₋₆alkyl; -S-(haloC₁₋₆alkyl), halo, haloC₁₋₆alkyl, -C(O)-C₁₋₆alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C₁₋₆alkyl, haloC₁₋₆alkyl or C₃₋₇cycloalkyl;

R⁵ is C₁₋₆alkyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, alkoxyC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkylC₁₋₆alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;

wherein phenyl, heterocyclyl and C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, C₃₋₇cycloalkylC₁₋₆alkenyl is optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substituted with C₁₋₆alkyl or haloC₁₋₆alkyl;

with the proviso that when R² is F, then X¹ is CH₂.


2. The compound according to the claim 1, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from the group consisting of pyrimidinyl, pyrazinyl, triazolyl, triazinyl, pyridinyl, pyridine oxide, pyrimidine oxide, pyrazine oxide, quinolinyl, quinazolinyl, quinoxalinyl, indazolyl, pyrazolopyrimidinyl, pyridopyrazinyl, triazolopyridazinyl, benzooxazolyl, oxadiazolyl, tetrazolyl, thiadiazolyl, oxazolyl, and thiazolyl, each of which is optionally substituted with one or more R³ substituents;

each R³ is independently selected from C₆₋₁₀aryl, benzyl, C₁₋₆alkyl, C₃₋₇cycloalkoxy, hydroxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, halo, haloC₁₋₆alkyl, OR⁵, CN, C(O)OC₁₋₆alkyl, OH, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH₂, and NR^aR^b, wherein R^a and R^b are independently H, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl or halo C₁₋₆alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C₃₋₇cycloalkyl, C₃₋₇cycloalkoxy, NH₂, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, -S-C₁₋₆alkyl; -S-(haloC₁₋₆alkyl), halo, haloC₁₋₆alkyl, -C(O)-C₁₋₆alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C₁₋₆alkyl, haloC₁₋₆alkyl or C₃₋₇cycloalkyl; and wherein R⁵ is C₁₋₆alkyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, alkoxyC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkylC₁₋₆alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;

wherein phenyl, heterocyclyl and C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, C₃₋₇cycloalkylC₁₋₆alkenyl is optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substituted with C₁₋₆alkyl or haloC₁₋₆alkyl; or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R⁴ is selected from:



wherein the * depicts the point of attachment to the nitrogen of the spiropiperidinyl moiety; and

wherein n is an integer between 1 and 3; p is 1 or 2, s is an integer between 1 and 4; and R^{3a}, R^{3b} and R^{3c} are independently selected from the group consisting of H, C₆₋₁₀aryl, benzyl, C₁₋₆alkyl, C₃₋₇cycloalkoxy, hydroxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, halo, haloC₁₋₆alkyl, OR⁵, CN, C(O)OC₁₋₆alkyl, OH, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH₂, and NR^aR^b, wherein R^a and R^b are independently H, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl or halo C₁₋₆alkyl;


wherein said aryl, heterocyclyl, heteroaryl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C₃₋₇cycloalkyl, C₃₋₇cycloalkoxy, NH₂, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, -S-C₁₋₆alkyl; -S-(haloC₁₋₆alkyl), halo, haloC₁₋₆alkyl, -C(O)-C₁₋₆alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C₁₋₆alkyl, haloC₁₋₆alkyl or C₃₋₇cycloalkyl;

R⁵ is C₁₋₆alkyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, alkoxyC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkylC₁₋₆alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;

wherein phenyl, heterocyclyl and C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, C₃₋₇cycloalkylC₁₋₆alkenyl is optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substituted with C₁₋₆alkyl or haloC₁₋₆alkyl; and wherein

R^{3d} is selected from H, C₆₋₁₀aryl, C₁₋₆alkyl, haloC₁₋₆alkyl, C₃₋₆cycloalkyl, 5- or 6-membered heteroaryl; and wherein said aryl, cycloalkyl, heteroaryl are further optionally substituted with one or more substituents independently selected from C₃₋₆cycloalkyl, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, halo and haloC₁₋₆alkyl; or a pharmaceutically acceptable salt thereof.

4. The compound according to any one of claims 1 to 3 wherein the compound has Formula (II); or a pharmaceutically acceptable salt thereof:



wherein R^{3a} , R^{3b} and R^{3c} are independently selected from the group consisting of H, C_{6-10} aryl, benzyl, C_{1-6} alkyl, C_{3-7} cycloalkoxy, hydroxy C_{1-6} alkyl, C_{1-6} alkoxy C_{1-6} alkyl, halo, halo C_{1-6} alkyl, OR^5 , CN, $C(O)OC_{1-6}$ alkyl, OH, C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, $-C(O)NH_2$, and NR^aR^b , wherein R^a and R^b are independently H, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl- C_{1-6} alkyl or halo C_{1-6} alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, C_{3-7} cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C_{3-7} cycloalkyl, C_{3-7} cycloalkoxy, NH_2 , C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, hydroxy C_{1-6} alkyl, $-S-C_{1-6}$ alkyl; $-S-(haloC_{1-6}alkyl)$, halo, halo C_{1-6} alkyl, $-C(O)-C_{1-6}$ alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C_{1-6} alkyl, halo C_{1-6} alkyl or C_{3-7} cycloalkyl;

R^5 is C_{1-6} alkyl, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, C_{3-7} cycloalkyl C_{1-6} alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;

wherein phenyl, heterocyclyl and C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkenyl is optionally substituted by one or more substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substituted with C_{1-6} alkyl or halo C_{1-6} alkyl; or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^{3a} is H; NH_2 or hydroxy C_{1-3} alkyl;

R^{3b} is selected from the group consisting of halo, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{3-7} cycloalkyl, OR^5 , 4-10 membered heterocyclyl, 5- to 10-membered heteroaryl, phenyl, and wherein said heterocyclyl, heteroaryl, phenyl and cycloalkyl is further optionally substituted with


one or more substituents independently selected from C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆

alkoxy, halo and haloC₁₋₆alkyl; wherein

R⁵ is C₁₋₆alkyl, haloC₁₋₆alkyl, C₃₋₇cycloalkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;

wherein phenyl, heterocyclyl or C₃₋₇cycloalkyl is optionally substituted by one or more substituents independently selected from C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy and halo; and R^{3c} is H or halo.

6. The compound according to any one of claims 1 to 3, wherein the compound has Formula (III); or a pharmaceutically acceptable salt thereof:



(III); wherein


wherein Y¹ is N or CR^{3c}; and wherein R^{3a}, R^{3b} and R^{3c} are independently selected from the group consisting of H, C₆₋₁₀aryl, benzyl, C₁₋₆alkyl, C₃₋₇cycloalkoxy, hydroxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, halo, haloC₁₋₆alkyl, OR⁵, CN, C(O)OC₁₋₆alkyl, OH, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH₂, and NR^aR^b, wherein R^a and R^b are independently H, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl or halo C₁₋₆alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C₃₋₇cycloalkyl, C₃₋₇cycloalkoxy, NH₂, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, -S-C₁₋₆alkyl; -S-(haloC₁₋₆alkyl), halo, haloC₁₋₆alkyl, -C(O)-C₁₋₆alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C₁₋₆alkyl, haloC₁₋₆alkyl or C₃₋₇cycloalkyl;

R⁵ is C₁₋₆alkyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, alkoxyC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkylC₁₋₆alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;

wherein phenyl, heterocyclyl and C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, C₃₋₇cycloalkylC₁₋₆akenyl is optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substituted with C₁₋₆alkyl or haloC₁₋₆alkyl; or a pharmaceutically acceptable salt thereof.

7. The compound according to any one of claims 1 to 3, wherein the compound has Formula (IV); or a pharmaceutically acceptable salt thereof:



R¹ is as defined in Formula I,

Y² is N or CR^{3b}; and wherein

R^{3a}, R^{3b}, R^{3c} and R^{3e} are independently selected from H, C₆₋₁₀aryl, benzyl, C₁₋₆alkyl, C₃₋₇cycloalkoxy, hydroxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, halo, haloC₁₋₆alkyl, OR⁵, CN, C(O)OC₁₋₆alkyl, OH, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH₂, and NR^aR^b, wherein R^a and R^b are independently H, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl or halo C₁₋₆alkyl;


wherein said aryl, heterocyclyl, heteroaryl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C₃₋₇cycloalkyl, C₃₋₇cycloalkoxy, NH₂, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, -S-C₁₋₆alkyl; -S-(haloC₁₋₆alkyl), halo, haloC₁₋₆alkyl, -C(O)-C₁₋₆alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C₁₋₆alkyl, haloC₁₋₆alkyl or C₃₋₇cycloalkyl;

R⁵ is C₁₋₆alkyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, alkoxyC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkylC₁₋₆alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;

wherein phenyl, heterocyclyl and C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, C₃₋₇cycloalkylC₁₋₆akenyl is optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆

alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substituted with C₁₋₆alkyl or haloC₁₋₆alkyl; or a pharmaceutically acceptable salt thereof.

8. The compound according to any one of claims 1 to 3, wherein the compound has Formula (V); or a pharmaceutically acceptable salt thereof:



Y³ is N, NR^{3d} or CR^{3a};

Y⁴ is N, NR^{3f} or CR^{3b};

Y⁵ is N, NR^{3g} or CR^{3c};

Y⁶ is N, NR^{3h} or CR^{3e};

wherein R^{3a}, R^{3b}, R^{3c}, R^{3e} are independently selected from H, C₆₋₁₀aryl, benzyl, C₁₋₆alkyl, C₃₋₇cycloalkoxy, hydroxyC₁₋₆alkyl, C₁₋₆alkoxyC₁₋₆alkyl, halo, haloC₁₋₆alkyl, OR⁵, CN, C(O)OC₁₋₆alkyl, OH, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, 5- to 10 membered heteroaryl, 4-10 membered heterocyclyl, -C(O)NH₂, and NR^aR^b, wherein R^a and R^b are independently H, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyl-C₁₋₆alkyl or halo C₁₋₆alkyl;

wherein said aryl, heterocyclyl, heteroaryl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkoxy are further optionally substituted with one or more substituents independently selected from OH, CN, C₃₋₇cycloalkyl, C₃₋₇cycloalkoxy, NH₂, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, hydroxyC₁₋₆alkyl, -S-C₁₋₆alkyl; -S-(haloC₁₋₆alkyl), halo, haloC₁₋₆alkyl, -C(O)-C₁₋₆alkyl, phenyl optionally further substituted with halo; and heteroaryl optionally substituted with halo, C₁₋₆alkyl, haloC₁₋₆alkyl or C₃₋₇cycloalkyl;


R⁵ is C₁₋₆alkyl, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, alkoxyC₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl, C₃₋₇cycloalkylC₁₋₆alkyl, phenyl, benzyl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl;


wherein phenyl, heterocyclyl and C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, C₃₋₇cycloalkylC₁₋₆alkenyl is optionally substituted by one or more substituents selected from C₁₋₆alkyl, C₁₋₆alkoxy, halo, phenyl optionally further substituted with halo; heterocyclyl optionally further substituted with C₁₋₆alkyl or haloC₁₋₆alkyl;

wherein R^{3d} , R^{3f} , R^{3g} , R^{3h} are independently selected from H, C_{6-10} aryl, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{3-6} cycloalkyl, 5- or 6-membered heteroaryl;

and wherein said aryl, heteroaryl, C_{3-6} cycloalkyl are further optionally substituted with one or more substituents independently selected from C_{3-6} cycloalkyl, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, halo and halo C_{1-6} alkyl; or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof,

wherein the moiety:  is selected from the following:



wherein R^{3a} , R^{3b} , R^{3c} , R^{4e} and R^{4f} are as defined in claim 8 and wherein * depicts the point of attachment to the nitrogen of the spiroperidinyll moiety.

10. The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is phenyl optionally substituted with one or two substituents independently selected from F and Cl.

11. The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X^1 is CH_2 and R^2 is F or H.

12. The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein X^1 is O and R^2 is H.

13. The compound according to claim 1, wherein the compound is selected from:

1-(4-chloro-3-fluorophenyl)-9-(1-(4-fluorophenyl)-1H-1,2,4-triazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(6-(trifluoromethyl)benzo[d]oxazol-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(2-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-5-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(6-(2,2-difluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-fluoro-6-(pyrrolidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-fluoro-6-(3-(trifluoromethyl)azetidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(4-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(4-(2,2,2-trifluoroethoxy)pyridin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

2-(1-(4-chloro-3-fluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecan-9-yl)-4-(4-fluorophenyl)pyridine 1-oxide;

9-(2-(5-azaspiro[2.3]hexan-5-yl)pyrimidin-4-yl)-1-(4-chloro-3-fluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(4-(5-azaspiro[2.3]hexan-5-yl)pyrimidin-2-yl)-1-(4-chloro-3-fluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(2-(3,3-dimethylazetidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-((1R,2R/1S,2S)-2-(trifluoromethyl)cyclopropyl)-1,2,4-oxadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-(3-(trifluoromethyl)bicyclo[1.1.1]pentan-1-yl)-1,2,4-oxadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(6-hydroxy-3-(pyrrolidin-1-yl)-1,2,4-triazin-5-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(6-(4-fluorophenyl)-4-methyl-3-oxo-3,4-dihydropyrazin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-cyclopentyl-1,2,4-triazin-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chlorophenyl)-9-(6-(4-fluorophenyl)pyridin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one

1-(4-chloro-3-fluorophenyl)-9-(4-(trifluoromethyl)pyrimidin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(7-(trifluoromethyl)quinazolin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-(4-fluorophenyl)oxazol-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(2-phenyl-2H-tetrazol-5-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-(3,3-difluoropyrrolidin-1-yl)-1,2,4-thiadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(3-(4-fluorophenyl)-1H-1,2,4-triazol-5-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-cyclohexyloxazol-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-(3-(trifluoromethyl)azetidin-1-yl)-1,2,4-thiadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-(pyrrolidin-1-yl)-1,2,4-thiadiazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-phenyl-1,3,4-oxadiazol-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(1-(4-fluorophenyl)-1H-pyrazol-3-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(2-(4-fluorophenyl)-2H-1,2,3-triazol-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chlorophenyl)-9-(6-(4-fluorophenyl)pyridin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

2-(1-(4-chloro-3-fluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecan-9-yl)-4-(4-fluorophenyl)pyridine 1-oxide;

4-(3-chlorophenoxy)-2-(1-(3,4-difluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecan-9-yl)pyridine 1-oxide;

9-(2-(5-azaspiro[2.3]hexan-5-yl)pyrimidin-4-yl)-1-(4-chloro-3-fluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(4-(5-azaspiro[2.3]hexan-5-yl)pyrimidin-2-yl)-1-(4-chloro-3-fluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-fluoro-6-(pyrrolidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(5-fluoro-6-(3-(trifluoromethyl)azetidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(4-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(4-(4-amino-4-(trifluoromethyl)piperidin-1-yl)pyrimidin-2-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(4-(4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)-1,3,5-triazin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-5-fluoro-6-(4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(6-(4-hydroxy-4-(trifluoromethyl)piperidin-1-yl)pyridazin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(6-amino-2-(3-hydroxy-3-methylazetidin-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(6-(3,3,4,4-tetrafluoropyrrolidin-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(6-(1,4-oxazepan-4-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-9-(2-amino-6-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(2-methyl-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

4-(1-(3,4-difluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecan-9-yl)-6-(1H-pyrazol-1-yl)pyrimidine-2-carbonitrile;

1-(3,4-difluorophenyl)-9-(2-methoxy-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(6-(1H-pyrazol-1-yl)-2-(trifluoromethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(2-morpholino-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(2-(dimethylamino)-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(6-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(6-(4-chloro-1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(6-(4-fluoro-1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(6-(3-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(6-(4-(trifluoromethyl)-1H-imidazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-5-fluoro-6-(1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(4-amino-6-(4-fluoro-1H-pyrazol-1-yl)-1,3,5-triazin-2-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(6-(oxetan-3-yloxy)-2-(trifluoromethyl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(6-(oxazol-2-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(6-amino-2-(pyridin-2-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecane-2-one;

1-(3,4-difluorophenyl)-9-(2-(2-hydroxypropan-2-yl)-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecane-2-one;

Synthesis 1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecane-2-one;

rac-1-(3,4-difluorophenyl)-9-(2-(1-hydroxymethyl)-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecane-2-one;

4-(1-(3,4-difluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecane-9-yl)-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-2-carboxamide;

9-(2-chloro-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

(R)-9-(2-chloro-6-((tetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

(S)-9-(2-chloro-6-((tetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

(R)-9-(4-chloro-6-((tetrahydrofuran-3-yl)oxy)pyrimidin-2-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(6-(4-fluoro-1H-pyrazol-1-yl)-2-morpholinopyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(4,4-difluorocyclohex-1-en-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(4-fluorophenyl-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecane-2-one;

9-(2-amino-6-(trifluoromethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(perfluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecane-2-one;

9-(2-amino-6-(1,1,2,2-tetrafluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(2-(hydroxynethyl)-6-(perfluoroethyl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecane-2-one;

1-(3,4-difluorophenyl)-9-(2-(2-hydroxypropan-2-yl)-6-(trifluoromethyl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(4-(2,2,2-trifluoroethoxy)pyridin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(4-chloro-3-fluorophenyl)-9-(6-(2,2-difluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(4-propoxypyrimidin-2-yl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-1-(3,4-difluorophenyl)-9-(6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-chloro-6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

(S)-9-(2-amino-6-(2,2,2-trifluoro-1-(oxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

(R)-9-(2-amino-6-(2,2,2-trifluoro-1-(oxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

(R)-9-(2-amino-6-(2,2,2-trifluoro-1-(oxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

(S)-9-(2-amino-6-(2,2,2-trifluoro-1-(oxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(3,3-difluorocyclobutoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(2,2,2-trifluoroethoxy-1,1-d₂)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-isopropoxypyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(2-hydroxyethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-9-(2-amino-6-(2,2,2-trifluoro-1-(3-methyloxetan-3-yl)ethoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(2,2,3,3,3-pentafluoropropoxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-9-(2-amino-6-((4,4-difluorotetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-9-(2-amino-6-(((3S,4S)-3-fluorotetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

(R)-9-(2-amino-6-((tetrahydro-2H-pyran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-9-(2-amino-6-(((3R,4R)-4-fluorotetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-((tetrahydro-2H-pyran-4-yl-4-d)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-9-(2-amino-6-((3-methyltetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-9-(2-amino-6-(((3S,4R)-4-fluorotetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-1-(3,4-difluorophenyl)-9-(6-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)oxy)-2-(hydroxymethyl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

rac-1-(3,4-difluorophenyl)-9-(6-(((3R,4R)-4-fluorotetrahydrofuran-3-yl)oxy)-2-(hydroxymethyl)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

(S)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((tetrahydrofuran-3-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

(S)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

(R)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

(R)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

(S)-1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;

rac ethyl 4-(1-(3,4-difluorophenyl)-2-oxo-1,9-diazaspiro[5.5]undecane-9-yl)-6-(((3S,4S)-4-fluorotetrahydrofuran-3-yl)oxy)pyrimidine-2-carboxylate;

(R)-9-(2-amino-6-((tetrahydrofuran-3-yl)amino)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one;

(R)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;

(S)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;

(S)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;

(R)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;

1-(3,4-difluorophenyl)-9-(2-(hydroxymethyl)-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;

9-(2-amino-6-(4-(trifluoromethyl)-1H-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;

(R)-9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;

(S)-9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;

(S)-9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;

(*R*)-9-(2-amino-6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;
rac-9-(2-amino-6-(perfluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-4-fluoro-1,9-diazaspiro[5.5]undecan-2-one;
rac-1-(3,4-difluorophenyl)-4-fluoro-9-(6-((tetrahydro-2H-pyran-4-yl)oxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(1,1-difluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one; and
1-(3,4-difluorophenyl)-4-fluoro-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one; or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

1-(3,4-difluorophenyl)-9-(6-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(4-(trifluoromethyl)-1*H*-pyrazol-1-yl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecane-2-one;
(*R*)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one,
(*S*)-9-(2-amino-6-((1,1,1-trifluoropropan-2-yl)oxy)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-3-oxa-1,9-diazaspiro[5.5]undecan-2-one;
9-(2-amino-6-(1,1-difluoroethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one; and
9-(2-amino-6-(trifluoromethyl)pyrimidin-4-yl)-1-(3,4-difluorophenyl)-1,9-diazaspiro[5.5]undecan-2-one.

15. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 14 and one or more pharmaceutically acceptable carriers.

16. A combination comprising a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, and one or more therapeutic agents.

17. A combination according to claim 16 wherein one or more therapeutic agents are independently selected from steroid; corticosteroids; glucocorticosteroids; non-steroidal glucocorticoid receptor agonists; leukotriene receptor antagonists (LTRAs) including LTB₄ antagonists, LTD₄ antagonists, Leukotriene A₄ hydrolase (LTA₄H) inhibitors, Cysteinyl-Leukotriene Receptor antagonists (including Montelukast, Pranlukast, Zafirlukast); a modulator of prostaglandin pathway (e.g. CRTH₂/DP₂ receptor antagonist); Bruton's tyrosine Kinase inhibitors (BTK inhibitors); PDE4 inhibitors; antihistamines; histamine H₄ receptor antagonist; H₁ receptor antagonists; beta-adrenergic drugs such as beta (β)-2-adrenoceptor agonists; anticholinergic drugs or and anticholinergic or antimuscarinic agents (e.g. M₂ and/or M₃ antagonists); nonsteroidal anti-inflammatory drugs ("NSAIDs"); analgesics; inhibitors of 5-lipoxygenase; inhibitors of FLAP (5-lipoxygenase activating protein); COX-2 selective inhibitors and statins.

18. A combination according to claim 16 comprising a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, and a leukotriene A₄ hydrolase inhibitor selected from the group consisting of (S)-3-amino-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2H-tetrazol-2-yl)butanoic acid; (S)-3-amino-4-(5-(4-(4-chlorophenoxy)-phenyl)-2H-tetrazol-2-yl)butanoic acid; (R)-3-amino-4-(5-(3-phenethoxyphenyl)-2H-tetrazol-2-yl)butanoic acid; (S)-3-amino-4-(5-(4-(*p*-tolylloxy)phenyl)-2H-tetrazol-2-yl)butanoic acid; (R)-3-amino-4-(5-(4-butoxyphenyl)-2H-tetrazol-2-yl)butanoic acid; acid; (R)-3-amino-4-(5-(4-phenethoxyphenyl)-2H-tetrazol-2-yl)butanoic acid; and (R)-3-amino-4-(5-(4-(4-chlorophenoxy)-phenyl)-2H-tetrazol-2-yl)butanoic acid; or pharmaceutically acceptable salt thereof.

19. A method of modulating LTC₄S activity in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.

20. A method of treating a disorder selected from allergic disorders, asthma, childhood wheezing, chronic obstructive pulmonary disease, aspirin exacerbated respiratory disease, bronchopulmonary dysplasia, cystic fibrosis, interstitial lung disease (e.g. sarcoidosis, pulmonary fibrosis, scleroderma lung disease, and usual interstitial in pneumonia), ear nose and throat diseases (e.g. sinusitis, rhinitis, nasal polyposis, rhinosinusitis, otitis media, and allergic eosinophilic esophagitis), eye diseases (e.g. conjunctivitis and giant papillary conjunctivitis), skin diseases (e.g. psoriasis, atopic dermatitis, eczema and chronic urticaria), rheumatic diseases (e.g. rheumatoid arthritis,


arthrosis, psoriasis arthritis, osteoarthritis, systemic lupus erythematosus, systemic sclerosis), vasculitis (e.g. Henoch-Schonlein purpura, Loffler's syndrome and Kawasaki disease), cardiovascular diseases (e.g. atherosclerosis, cerebrovascular diseases, acute ischemic heart attacks and post-heart attack treatment), gastrointestinal diseases (e.g. eosinophilic diseases in the gastrointestinal system, inflammatory bowel disease, irritable bowel syndrome, colitis, celiac and gastric haemorrhagia), urologic diseases (e.g. glomerulonephritis, interstitial cystitis, nephritis, nephropathy, nephrotic syndrome, hepatorenal syndrome, and nephrotoxicity), diseases of the central nervous system (e.g. cerebral ischemia, spinal cord injury, migraine, multiple sclerosis, and sleep-disordered breathing), endocrine diseases (e.g. autoimmune thyroiditis, diabetes-related inflammation), urticaria, anaphylaxis, angioedema, oedema in Kwashiorkor, dysmenorrhoea, burn-induced oxidative injury, multiple trauma, pain (inflammatory and neuropathic), endotoxin shock, sepsis, bacterial infections (e.g. from *Helicobacter pylori*, *Pseudomonas aeruginosa* or *Shigella dysenteriae*), fungal infections (e.g. vulvovaginal candidiasis), viral infections (e.g. hepatitis, meningitis, parainfluenza and respiratory syncytial virus), hypereosinophilic syndrome, and malignancies (e.g. Hodgkin's lymphoma, leukemia (e.g. eosinophil leukemia and chronic myelogenous leukemia), mastocytosis, polycytemia vera, and ovarian carcinoma) wherein the method comprises administering to the subject a therapeutically effective amount of the compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.


21. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, for use as a medicament, in particular for inhibiting LTC₄S activity.

22. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder selected from allergic disorders, asthma, childhood wheezing, chronic obstructive pulmonary disease, aspirin exacerbated respiratory disease, bronchopulmonary dysplasia, cystic fibrosis, interstitial lung disease (e.g. sarcoidosis, pulmonary fibrosis, scleroderma lung disease, and usual interstitial pneumonia), ear nose and throat diseases (e.g. sinusitis, rhinitis, nasal polyposis, rhinosinusitis, otitis media, and allergic eosinophilic esophagitis), eye diseases (e.g. conjunctivitis and giant papillary conjunctivitis), skin diseases (e.g. psoriasis, atopic dermatitis, eczema and chronic urticaria), rheumatic diseases (e.g. rheumatoid arthritis, arthrosis, psoriasis arthritis, osteoarthritis, systemic lupus erythematosus, systemic sclerosis), vasculitis (e.g. Henoch-Schonlein purpura, Loffler's syndrome and Kawasaki disease), cardiovascular diseases (e.g. atherosclerosis, cerebrovascular diseases, acute ischemic heart attacks and post-heart attack treatment), gastrointestinal diseases (e.g.

eosinophilic diseases in the gastrointestinal system, inflammatory bowel disease, irritable bowel syndrome, colitis, celiac and gastric haemorrhagia), urologic diseases (e.g. glomerulonephritis, interstitial cystitis, nephritis, nephropathy, nephrotic syndrome, hepatorenal syndrome, and nephrotoxicity), diseases of the central nervous system (e.g. cerebral ischemia, spinal cord injury, migraine, multiple sclerosis, and sleep-disordered breathing), endocrine diseases (e.g. autoimmune thyroiditis, diabetes-related inflammation), urticaria, anaphylaxis, angioedema, oedema in Kwashiorkor, dysmenorrhoea, burn-induced oxidative injury, multiple trauma, pain (inflammatory and neuropathic), endotoxin shock, sepsis, bacterial infections (e.g. from *Helicobacter pylori*, *Pseudomonas aeruginosa* or *Shigella dysenteriae*), fungal infections (e.g. vulvovaginal candidiasis), viral infections (e.g. hepatitis, meningitis, parainfluenza and respiratory syncytial virus), hypereosinophilic syndrome, and malignancies (e.g. Hodgkin's lymphoma, leukemia (e.g. eosinophil leukemia and chronic myelogenous leukemia), mastocytosis, polycytemia vera, and ovarian carcinoma).

23. A compound of selected from the group consisting of:





wherein PG is a nitrogen protecting group; and PG² is a carboxylic acid protecting group; PG³ is carbobenzyloxy (Cbz) or *tert*-butoxycarbonyl (BOC); each R^{1a} is halo, each R^{1b} is independently selected from F and Cl; v is 1-3, and R¹ is phenyl optionally substituted with one, two or three halo substituents.